BRAF与MEK联合抑制联合PD-1阻断免疫治疗用于BRAF突变黑色素瘤
这项首次人体临床试验纳入15例BRAFV600突变转移性黑色素瘤患者,评估达拉非尼、曲美替尼联合帕博利珠单抗治疗。11例(73%)发生3/4级治疗相关不良事件,最常见为肝功能检查升高和发热;11例(73%,95%CI 45-92%)获得客观缓解,6例(40%,95%CI 16-68%)在中位随访27个月时仍持续缓解。研究提示该三联疗法可能通过提高持久抗肿瘤缓解频率使部分患者获益。
要点
- 15例BRAFV600突变转移性黑色素瘤患者接受达拉非尼+曲美替尼+帕博利珠单抗三联治疗。
- 11例(73%)发生3/4级治疗相关不良事件,最常见为肝功能检查升高和发热。
- 11例(73%,95%CI 45-92%)客观缓解,6例(40%,95%CI 16-68%)在中位随访27个月时持续缓解。
核心结论
- 该研究提示该三联联合治疗可能通过提高持久抗肿瘤缓解的频率使部分BRAFV600突变转移性黑色素瘤患者获益。
研究设计与样本
- 首次人体临床试验,纳入15例BRAFV600突变转移性黑色素瘤患者,接受达拉非尼、曲美替尼和帕博利珠单抗治疗(NCT02130466)。
主要发现
- 11例(73%)发生3/4级治疗相关不良事件,最常见为肝功能检查升高和发热,多数经药物中断或停用抗PD-1抗体或靶向治疗组合后缓解。
- 11例(73%;95%置信区间=45-92%)获得客观缓解。
- 6例(40%;95%置信区间=16-68%)在中位随访27个月(范围=10.3-38.4+个月)时仍持续缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oncogene-targeted therapy with B-Raf proto-oncogene (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors induces a high initial response rate in patients with BRAFV600-mutated melanoma, with a median duration of response of approximately 1 year1-3. Immunotherapy with antibodies to programmed death 1 (PD-1) produces lower response rates but with long response duration. Preclinical models suggest that combining BRAF and MEK inhibitors with PD-1 blockade therapy improves antitumor activity4-6, which may provide additional treatment options for patients unlikely to have long-lasting responses to either mode of therapy alone. We enrolled 15 patients with BRAFV600-mutated metastatic melanoma in a first-in-human clinical trial of dabrafenib, trametinib and pembrolizumab ( NCT02130466 ). Eleven patients (73%) experienced grade 3/4 treatment-related adverse events, the most common being elevation of liver function tests and pyrexia, most of which resolved with drug interruption or discontinuation of either the anti-PD-1 antibody or the targeted therapy combination. Eleven patients (73%; 95% confidence interval = 45-92%) had an objective response, and six (40%; 95% confidence interval = 16-68%) continued with a response at a median follow-up of 27 months (range = 10.3-38.4+ months) for all patients. This study suggests that this triple-combined therapy may benefit a subset of patients with BRAFV600-mutated metastatic melanoma by increasing the frequency of long-lasting antitumor responses.
引用
- Ribas A, Lawrence D, Atkinson V, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019. PMID: 31171879. doi:10.1038/s41591-019-0476-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。